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World Heart Day, celebrated annually on September 29, was established by the World 28 
Heart Federation to generate awareness for cardiovascular disease (CVD) (7). CVD truly is a 29 
global disease that affects millions of people worldwide. While the types and manifestations of 30 
CVD differ between certain parts of the world, the various CVDs share the unfortunate feature of 31 
leading to significant morbidity and mortality. In addition, CVDs may profoundly affect the quality 32 
of life of affected individuals and make affected individuals more prone to suffering unfavorable 33 
outcomes in emerging diseases such as COVID-19 (14, 31). Not surprisingly, the public health 34 
relevance and fiscal consequences of CVDs are substantial. The impact of CVD across the 35 
world, strategies for addressing several of the major knowledge and treatment gaps, and the 36 
role of the World Heart Federation in addressing the burden CVD have been outlined eloquently 37 
in an editorial by Maarman, Chakafana and Sliwa in this issue of AJP Lung (20). The authors 38 
remind us that after 20 years, the importance of World Heart Day is still eminent. 39 
While CVD without a doubt represents a major global health burden, one may wonder 40 
why a pulmonary journal such as AJP Lung is highlighting World Heart Day and why a 41 
pulmonologist is writing an accompanying editorial. The answer is easy: nearly all pulmonary 42 
diseases have the potential to affect the right side of the heart (12). This right heart involvement, 43 
which can be observed in acute as well as chronic lung disease, may either occur indirectly and 44 
subsequentially (usually as a consequence of the development of acute and/or chronic 45 
pulmonary hypertension [PH) or concomitantly (through a pathophysiologic process that targets 46 
both the lung and heart [e.g., cigarette smoke exposure, side effects of chemotherapeutics, 47 
microvascular thrombosis in sepsis and/or ARDS]). In addition, several common diseases such 48 
as diabetes, hyperlipidemia or obstructive sleep apnea induce wide-spread endothelial cell 49 
dysfunction and simultaneously target and affect both the lung as well as the heart (both the 50 
right and left heart). In fact, right heart abnormalities in subjects exposed to cigarette smoke 51 
may occur even before signs of lung disease are observed (27). With regards to PH 52 
development in acute or chronic lung disease it is important to note that, no matter what the 53 
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underlying lung disease is, as soon as PH and cor pulmonale develop, morbidity and mortality 54 
of affected individuals increase significantly (2, 5, 21, 25). Another interesting observation is that, 55 
while the “typical” phenotype of right heart involvement in chronic lung disease is that of an 56 
enlarged and hypertrophied right ventricle (RV) and a dilated right atrium, in a subset of patients 57 
with chronic obstructive pulmonary disease (COPD), a small and atrophied right heart has been 58 
described (11), possibly representing a process of cardiopenia that may be similar to the 59 
sarcopenia that can be seen in this patient population. 60 
On the other hand, it has long been known that any type of left heart disease, can cause 61 
lung disease and right heart abnormalities (24). This typically occurs through the development 62 
of PH and subsequent right heart congestion. In addition, given the shared pericardial sac as 63 
well as shared myocardial fibers, mechanical changes associated with left heart enlargement 64 
may directly affect the geometry and mechanics of the RV, thus leading to RV dysfunction. In 65 
this context, it is worthwhile noting that the interventricular septum contributes ~40% to the RV 66 
ejection fraction (26). In addition to PH, the lung may be affected by left heart disease through 67 
the development of pulmonary edema, pleural effusions, compressive atelectasis due to left 68 
heart enlargement, or pulmonary emboli. Lastly, several drugs used to treat CVD or its 69 
consequences may harm the lung and lead to alveolar hemorrhage (anticoagulants), chronic 70 
cough (ACE inhibitors), pulmonary fibrosis (amiodarone) or acute lung injury (amiodarone). 71 
Given the intricacies of lung/heart interactions, clinicians and researchers have coined 72 
the terms “cardiopulmonary system” or “cardiopulmonary axis”. This is why a pulmonary journal 73 
like AJP Lung indeed should pay attention to the heart and the cardiovascular system (and why 74 
cardiovascular journals, in turn, should pay attention to diseases of the lung). Given the global 75 
burden of CVD as well as respiratory diseases such as COPD, obstructive sleep apnea and 76 
ARDS, and given the high prevalence of combined heart and lung disease throughout the world, 77 
involvement of the cardiopulmonary axis is a global issue (4). In addition, since many CVDs and 78 
respiratory diseases disproportionally affect underrepresented minorities, involvement of the 79 
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cardiopulmonary axis represents a significant problem in these populations (30). It is therefore 80 
timely and relevant that AJP Lung is highlighting the importance of World Heart Day in this 81 
current issue. 82 
In addition to highlighting World Heart Day, AJP Lung has addressed the role of 83 
cardiopulmonary interactions by publishing several insightful and thought-provoking manuscripts 84 
investigating the role of the right heart and cardiopulmonary interaction in various pulmonary 85 
conditions or respiratory exposures. These manuscripts center on a variety of topics such as 86 
sex differences and estrogen signaling in RV function in PH (9, 18); effects of perinatal 87 
hyperoxia or hypoxia on RV function later in life (10, 15); effects of HIV, opioids or vaping on 88 
endothelial function and cardiorespiratory parameters (1, 3); bone morphogenetic protein 89 
receptor 2 (BMPR2) regulation of insulin and glucose signaling in cardiomyocytes (13); 90 
interdependence of RV glucose uptake, hypoxia and β-adrenergic receptor signaling in PH (28); 91 
effects of pulmonary vascular thrombospondin 1/CD47 signaling on RV afterload in sickle cell 92 
disease (22); differences in mesothelial mobilization between the developing lung and heart (19); 93 
and effects of episodic hypercapnic stimulation on respiratory-cardiovascular coupling in volume 94 
overload heart failure (6). Two studies assessed the effects of established treatments for 95 
pulmonary arterial hypertension (PAH; used in combination with other established or emerging 96 
PAH treatments) on RV adaptation using novel endpoints or novel delivery methods (16, 23). A 97 
review article focused on the role of angiogenesis in the development of right heart failure in PH 98 
(8). A review in AJP Lung’s sister journal Physiology discussed physiological aspects of RV-99 
pulmonary vascular interactions (29). In conglomerate, these studies and reviews demonstrate 100 
tight interactions between the respiratory and the cardiovascular systems and reveal that 101 
several exposures, environmental stimuli and intrinsic factors previously thought to only affect 102 
the lung actually engage pathways that are active in both organ systems. In addition, several of 103 
the above mentioned studies revealed that cardiovascular adaptation in the setting of lung 104 
disease is dependent on biologically relevant factors such as sex, age, metabolism and genetics. 105 
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However, while we have learned a great deal about cardiopulmonary interactions in the 106 
setting of lung disease, several knowledge gaps remain: First, it often is difficult to dissect 107 
whether interventions shown to improve RV adaptation exert their RV-protective effects directly 108 
by targeting the RV or more indirectly by lowering RV afterload through pulmonary vascular 109 
effects. Studies employing pressure-volume loops, pulmonary artery banding models or cultured 110 
isolated RV cardiomyocytes are needed to answer this question (17). Second, while we have 111 
just started to understand that sex/gender, age and lifestyle factors such as exercise and diet 112 
are clinically important modifiers of cardiopulmonary interactions, more studies are needed to 113 
understand the underlying mechanisms (17). This, in turn, may allow for the development of 114 
novel, personalized treatment strategies aimed at improving cardiopulmonary adaptations in 115 
chronic lung and/or heart diseases. Along those lines, race and socioeconomic factors are 116 
significant disease modifiers in both the cardiovascular system and the lung, and their effects on 117 
the cardiopulmonary axis need to be studied in more detail (30). Third, while it is well known that 118 
many interventions in chronic lung or cardiovascular disease improve respiratory or 119 
cardiovascular function, respectively, effects of novel respiratory interventions on the 120 
cardiovascular system (and vice versa) need to be studied in more detail. Lastly, given the 121 
current COVID-19 pandemic, and given the frequent lung and occasional heart involvement in 122 
this disease (14, 31), it is imperative that we better understand short-term as well as long-term 123 
cardiopulmonary complications of and cardiopulmonary interactions in SARS-CoV-2 infection.  124 
Importantly, all these knowledge gaps have significant global implications that must not 125 
be neglected. Addressing these gaps therefore should involve a coordinated global effort, so 126 
that results from basic, translational and clinical studies are maximally generalizable. Multi-127 
country organizations such as the World Heart Federation and Pulmonary Vascular Research 128 
Institute have the resources and wherewithal to lead global efforts in the fight against 129 
cardiopulmonary disease (4, 20). In fact, both organizations have made major contributions in 130 
this field by 1) supporting research, education and clinical care, 2) establishing international 131 
6
working groups and facilitating multi-country collaborations, 3) providing training programs, 4) 132 
pursuing advocacy and public outreach, and 5) establishing global registries. 133 
In summary, diseases of the lung or the cardiovascular system should not be looked at 134 
in isolation. An integrative approach that encompasses assessing effects of exposures and 135 
interventions on the entire cardiopulmonary axis is likely to maximize scientific insight and 136 
enhance clinical responses. World Heart Day reminds us that pulmonologists and researchers 137 
studying the respiratory system should worry about the heart, and that CVD specialists and 138 
researchers should pay attention to the lung. Addressing the cardiopulmonary system as a 139 
whole, ideally while leveraging the power of the exciting -omics, genetic and phenotyping tools 140 
that are currently available, will facilitate the development of novel, personalized pharmacologic 141 
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